Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

India's Natco Will File India, Nepal Compulsory License Applications For Generic Versions Of Pfizer's Cancer Drug Celzentry

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Natco Pharma told PharmAsia News it plans to file a compulsory license application to sell a generic version of Pfizer's HIV/AIDS drug Celzentry (maraviroc) in Nepal and India, the third such application by the firm, which has cited the high cost of the drugs to the patent office in India as the backbone of its cases
Advertisement

Related Content

Senior Judges At Indian Legal Symposium Call For Review Of Patent Act
Senior Judges At Indian Legal Symposium Call For Review Of Patent Act
PharmAsia News India Pharma Roundup: Natco, Strides Arcolab, Glenmark, Ranbaxy/Pfizer, Merck
Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva
Indian Court Allows Cipla to Continue Sales of Generic Roche Lung Cancer Drug Tarceva
Advertisement
UsernamePublicRestriction

Register

SC068150

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel